For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Similarly, 65%, 26%, and 9% of participants treated with tirzepatide 10 mg (N=239) regained less than 5%, 5% to 10%, and 10% or more weight from nadir to week 176, respectively. Among participants ...

New research shows that people who take the weight-loss drug tirzepatide can keep most of the weight off for at least three ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.* New research to be presented at this year ...